Genetic risk factors of Alzheimer’s disease
DOI:
https://doi.org/10.15584/ejcem.2019.1.10Keywords:
autosomal genetic mutations, early-onset Alzheimer Disease, genetic polymorphisms, late-onset Alzheimer DiseaseAbstract
Introduction. Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases, which is a serious health problem for societies that live longer. Spontaneous dominant mutations and polymorphisms of selected genes play an important role in development of AD.
Aim. Several polymorphisms in selected genes strongly associated with development of Alzheimer’s disease were highlighted in this review: APOE, CYP46, APP, PSEN1, PSEN2, UBQLN1, BACE1, PRND, APBB2, TOMM 40. These gene polymorphisms have a significant role in the development of Alzheimer’s disease and they have potential to be biomarkers. Researchers combine efforts to find significant polymorphisms that would ensure that a person is predisposed to the occurrence of disease symptoms. This topic is often taken up by scientists seeking to develop effective genetic tests for diagnosing AD.
Material and methods. Analysis of literature from web of knowledge: Web of Science (all database), NCBI and PubMed.
Results. We reviewed the selected important genes and polymorphisms which are most often associated with development of AD.
Conclusion. It should be noted that nowadays scientists strive not to focus on only one polymorphism in the gene but on several polymorphisms in different genes concomitantly and above all on interactions between them to the diagnosis of this disease. Only this approach to AD will contribute to the creation of appropriate identification methods. Moreover, we should use the new generation tools - the platform for collecting data and personalized medicine.
Downloads
References
Li Z, Xiong Z, Manor LC, Cao H, Li T. Integrative computational evaluation of genetic markers for Alzheimer's disease. Saudi J Biol Sci. 2018;25(5):996-1002.
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377(9770):1019-1031.
Verheijen J, Sleegers K. Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. Trends in Genetics. 2018;34(6):434-447.
Mendez MF. Early-onset Alzheimer's Disease: Nonamnestic Subtypes and Type 2 AD. Archives of Medical Research. 2012;43(8):677-685.
Wallin A. Current definition and classification of dementia diseases. Acta Neurologica Scandinavica. 1996;94:39-44.
Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurology. 2010;9(8):793-806.
Bagyinszky E, Lee HM, Van Giau V, et al. PSEN1 p.Thr116Ile Variant in Two Korean Families with Young Onset Alzheimer's Disease. Int J Mol Sci. 2018;19(9).
Zimny A, Bladowska J, Neska M, et al. Quantitative MR evaluation of atrophy, as well as perfusion and diffusion alterations within hippocampi in patients with Alzheimer's disease and mild cognitive impairment. Medical Science Monitor. 2013;19:86-94.
Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers & Dementia. 2011;7(3):270-279.
Alzheimer's disease facts and figures. Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2017;13(4):325-373.
Karki R, Pandya D, Elston RC, Ferlini C. Defining "mutation" and "polymorphism" in the era of personal genomics. Bmc Medical Genomics. 2015;8.
Vogel and Motulsky's Human Genetics, Fourth Edition. Vogel and Motulsky's Human Genetics, Fourth Edition: Problems and Approaches. 2010:1-981.
Strittmatter WJ, Saunders AM, Schmechel D, et al. Apoliporotein-E - high-avidity binding to beta-amyloid and increased frequencyof type-4 allele in late-onset familial Alzheimer-Disease. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(5):1977-1981.
Nalbantoglu J, Gilfix BM, Bertrand P, et al. Predictive value of Apolipoprotein-E genotiping in Azheimers-Disease - results of an autopsy series and an analysis of several combined studies. Annals of Neurology. 1994;36(6):889-895.
Huang Y-WA, Zhou B, Wernig M, Südhof TC. ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Aβ Secretion. Cell. 2017;168(3):427-441.e421.
Willis F, Graff-Radford N, Pinto M, et al. Apolipoprotein is an element of 4 allele frequency in young Africans of Ugandan descent versus African Americans. Journal of the National Medical Association. 2003;95(1):71-76.
Gerdes LU, Klausen IC, Sihm I, Faergeman O. Apolipoprotein-E polymorphism in a Danish population compared to findings in 45 other study populations around the world. Genetic Epidemiology. 1992;9(3):155-167.
Wang C, Yu J-T, Wang H-F, et al. Meta-Analysis of Peripheral Blood Apolipoprotein E Levels in Alzheimer's Disease. Plos One. 2014;9(2).
Nunomura A, Chiba S, Eto M, Saito M, Makino I, Miyagishi T. Apolipoprotein E polymorphism and susceptibility to early- and late-onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. Neuroscience Letters. 1996;206(1):17-20.
Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. Apolipoprotein-E polymorphism and Alzheimers-Disease. Lancet. 1993;342(8873):697-699.
Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921-923.
Bang OY, Kwak YT, Joo IS, Huh K. Important link between dementia subtype and apolipoprotein E: a meta-analysis. Yonsei Med J. 2003;44(3):401-413.
Nielsen AS, Ravid R, Kamphorst W, Jorgensen OS. Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. Journal of Alzheimer's disease : JAD. 2003;5(2):119-125.
Engelborghs S, Dermaut B, Goeman J, et al. Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. Journal of Neurology Neurosurgery and Psychiatry. 2003;74(8):1148-1151.
Liu C-C, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nature Reviews Neurology. 2013;9(2):106-118.
Heyman A, Fillenbaum GG, Welsh-Bohmer KA, et al. Cerebral infarcts in patients with autopsy-proven Alzheimer's disease - CERAD, part XVIII. Neurology. 1998;51(1):159-162.
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nature Genetics. 2007;39(1):17-23.
Golanska E, Hulas-Bigoszewska K, Sieruta M, et al. Earlier Onset of Alzheimer's Disease: Risk Polymorphisms Within PRNP, PRND, CYP46, and APOE Genes. Journal of Alzheimers Disease. 2009;17(2):359-368.
Golanska E, Hulas-Bigoszewska K, Wojcik I, et al. CYP46: A risk factor for Alzheimer's disease or a coincidence? Neuroscience Letters. 2005;383(1-2):105-108.
Juhasz A, Rimanoczy A, Boda K, et al. CYP46 T/C polymorphism is not associated with Alzheimer's dementia in a population from Hungary. Neurochemical Research. 2005;30(8):943-948.
Combarros O, Infante J, Llorca J, Berciano J. Genetic association of CYP46 and risk for Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 2004;18(3-4):257-260.
Ertekin-Taner N. Genetics of Alzheimer's Disease: A centennial review. Neurologic Clinics. 2007;25(3):611-67.
Pesz KM, Misiak B, Sąsiadek MM, Leszek JR. Genetyczne podstawy zespołów otępiennych. Choroby otępienne. Teoria i praktyka. Wrocław: Continuo; 2011:45-48.
Lanoiselee H-M, Nicolas G, Wallon D, et al. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases. Plos Medicine. 2017;14(3).
Giau VV, Wang MJ, Bagyinszky E, Youn YC, An SSA, Kim S. Novel PSEN1 p.Gly417Ala mutation in a Korean patient with early-onset Alzheimer's disease with parkinsonism. Neurobiol Aging. 2018;72:188.e113-188.e117.
Haapasalo A, Viswanathan J, Bertram L, Soininen H, Tanzi RE, Hiltunen M. Emerging role of Alzheimer's disease-associated ubiquilin-1 in protein aggregation. Biochem Soc Trans. 2010;38(Pt 1):150-155.
El Ayadi A, Stieren ES, Barral JM, Boehning D. Ubiquilin-1 and protein quality control in Alzheimer disease. Prion. 2013;7(2):164-169.
Zhang T, Jia Y. Meta-analysis of Ubiquilin1 gene polymorphism and Alzheimer's disease risk. Med Sci Monit. 2014;20:2250-2255.
Chuo LJ, Wu ST, Chang HI, Kuo YM. Extremely rare incidence of the UBQLN1 polymorphism (UBQ-8i) in Taiwan Chinese with Alzheimer's disease. Neurosci Lett. 2010;475(2):108-109.
Natunen T, Takalo M, Kemppainen S, et al. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models. Neurobiol Dis. 2016;85:187-205.
Beekes M, Thomzig A, Schulz-Schaeffer WJ, Burger R. Is there a risk of prion-like disease transmission by Alzheimer- or Parkinson-associated protein particles? Acta Neuropathol. 2014;128(4):463-476.
Flirski M, Sieruta M, Golanska E, Kloszewska I, Liberski PP, Sobow T. PRND 3 ' UTR polymorphism may be associated with behavioral disturbances in Alzheimer disease. Prion. 2012;6(1):73-80.
Li YH, Hollingworth P, Moore P, et al. Genetic association of the APP binding protein 2 gene (APBB2) with late onset Alzheimer disease. Human Mutation. 2005;25(3):270-277.
Zeitlow K, Charlambous L, Ng I, et al. The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 2017;1863(11):2973-2986.
Kwong JQ, Beal MF, Manfredi G. The role of mitochondria in inherited neurodegenerative diseases. Journal of Neurochemistry. 2006;97(6):1659-1675.
Lyall DM, Harris SE, Bastin ME, et al. Alzheimer's disease susceptibility genes APOE and TOMM40, and brain white matter integrity in the Lothian Birth Cohort 1936. Neurobiology of Aging. 2014;35(6).
Wennberg AM, Spira AP, Pettigrew C, et al. Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. J Neurol Sci. 2016;365:89-95.
Yu L, Qian S, Wei S. Identification of a noncoding RNAmediated gene pairbased regulatory module in Alzheimer's disease. Mol Med Rep. 2018;18(2):2164-2170.
Tasaki S, Gaiteri C, Mostafavi S, De Jager PL, Bennett DA. The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia. Frontiers in Neuroscience. 2018; 12:699. DOI: 10.3389/fnins.2018.00699
Bis JC, Jian X, Kunkle BW, et al. Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. Molecular psychiatry. 2018; DOI: 10.1038/s41380-018-0112-7. [Epub ahead of print].
Kwok MK, Lin SL, Schooling CM. Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. EBioMedicine. 2018; 7:461-470,DOI:10.1016/j.ebiom.2018.10.001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
